Key Reasons to Add Crown Castle Stock to Your Portfolio Now — Positive
CCI Zacks Investment Research — December 23, 2025CCI is positioned to benefit from rising wireless data demand, long-term carrier leases and a solid balance sheet supporting network expansion.
Gold firmer, silver sharply up; both hit new record highs — Positive
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL SIL SILJ SIVR SLV SLVP UGL Kitco — December 23, 2025Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up — Positive
NVO Zacks Investment Research — December 23, 2025NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
Ford or General Motors: Which Stock to Buy Heading into 2026? — Positive
F GM Zacks Investment Research — December 23, 2025GM's U.S. leadership, China rebound, software growth and aggressive buybacks give it an edge over Ford as 2026 approaches.
COIN to Buy Clearing Company: Is it Raising Prediction Market Stake? — Neutral
COIN Zacks Investment Research — December 23, 2025COIN to acquire The Clearing Company as it deepens its move into prediction markets and diversifies beyond crypto trading.
Ichor Holdings (ICHR) is rated BUY, with fundamentals expected to improve in 2026 and a bottoming share price creating an attractive entry point. ICHR's new CEO is focused on operational discipline and margin expansion, leveraging proprietary products and a robust M&A strategy supported by prudent leverage. Revenue growth from key customers Lam Research and Applied Materials is projected to accelerate ICHR's production and gross margins toward historical levels.
Could Novo Nordisk's New Weight-Loss Pill Be Just What Its Stock Needs? — Positive
NVO Investopedia — December 23, 2025Could a new weight-loss pill be just what Novo Nordisk (NVO) needs to revive its stock?
3 Self-Driving Tech Stocks to Ride into 2026 as AV Race Heats Up — Neutral
BIDU GOOG UBER Zacks Investment Research — December 23, 2025BIDU, GOOGL and UBER are steering into 2026 with bold AV bets as the race to scale robotaxis globally intensifies.
GILD Exercises Option to License Assembly Bio's Herpes Programs — Neutral
GILD Zacks Investment Research — December 23, 2025Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling — Negative
JNJ New York Post — December 23, 2025The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff.
Spartan Capital Securities, LLC Serves as Sales Agent in Hyperscale Data, Inc.'s $50 Million At-the-Market Offering — Neutral
GPUS GlobeNewsWire — December 23, 2025New York, NY, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, today announced that Hyperscale Data, Inc. (NYSE American: GPUS) has entered into a sales agreement under which Spartan Capital Securities will act as the Company's sales agent for an at-the-market equity offering program.
SLF Stock Near 52-Week High: Time to Hold Despite Expensive Valuation? — Positive
SLF Zacks Investment Research — December 23, 2025Sun Life Financial stock gains from growing asset management businesses, its focus on Asia operations, as well as scaling up and integrating U.S. operations.
2 Stocks for You to Buy From the Growing Outsourcing Market — Neutral
CGEMY TNET Zacks Investment Research — December 23, 2025The rising demand for BPO, AI and ML drives the Zacks Outsourcing industry's growth. Increasing cybersecurity risks demand more outsourcing options.
CarMax, Inc. Investors: January 2, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP — Neutral
KMX PRNewsWire — December 23, 2025RADNOR, Pa. , Dec. 23, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that an amended securities class action lawsuit has been filed against CarMax, Inc. ("CarMax") (NYSE: KMX) which expands the class period to include those who purchased or otherwise acquired CarMax securities between June 20, 2025, and November 5, 2025, inclusive (the "Class Period").
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Inspire Medical Systems, Inc. (INSP) — Neutral
INSP GlobeNewsWire — December 23, 2025NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit was filed on December 22, 2024 in the United States District Court for the District of Minnesota on behalf of all persons or entities who purchased or otherwise acquired Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP) securities between August 6, 2024 and August 4, 2025, inclusive (the “Class Period”).
Gold Mining ETF (GDXJ) Hits New 52-Week High — Neutral
GDXJ Zacks Investment Research — December 23, 2025GDXJ just broke to a new 52-week high as as gold demand surges on Fed rate-cut expectations, central bank buying and economic uncertainties.
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies — Positive
CRSP Zacks Investment Research — December 23, 2025CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
Altria vs. Philip Morris: Who Leads Tobacco's Next Chapter? — Positive
MO PM Zacks Investment Research — December 23, 2025MO and PM push smoke-free growth, using pricing power, innovation and discipline to navigate declining cigarette demand and reshape tobacco's future.
Alibaba Stock Plunges 14.4% in 3 Months: Time to Buy, Sell or Hold? — Negative
BABA Zacks Investment Research — December 23, 2025BABA shares slides 14.4% in three months as profits crater despite revenue growth, with heavy AI and cloud spending testing investor patience.
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff — Positive
BMY Seeking Alpha — December 23, 2025Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of exclusivity risks, BMY's growth portfolio delivered 18% growth in Q3 and now exceeds 50% of business mix. Robust free cash flow margins (>30%) and a 4.7% yield provide BMY investors with attractive compensation while awaiting pipeline catalysts.